Part 1: Navigating The Dual Faces of the Ketamine Treatment Conundrum in the treatment of Mental Health Disorders: 

One of the most contentious issues in contemporary mental health discourse is the debate surrounding Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD), and ketamine’s role in therapeutic interventions. Professionals and patients alike are divided over the dual potential of ketamine treatment as a revolutionary healing aid or a contentious choice in the realm of psychedelic therapy.

Since the 1970s, ketamine has been referenced for its mood-enhancing properties, but its efficacy in treating depression entered the scientific arena at the turn of the millennium with the commencement of the first human clinical trials. An increasing body of evidence suggests that this compound not only has antidepressant properties, but also plays an important role in reducing suicidal tendencies. As part of a landmark decision, the FDA sanctioned the use of (S)-ketamine, via the SpravatoTM nasal spray, specifically for the treatment of TRD, acknowledging the positive impact it has on bipolar depression and related mood disorders. With this endorsement, ketamine has gained recognition as a fast-acting antidepressant, which opens up new possibilities for the treatment of MDD and TRD with an immediate symptomatic response.

The symptoms of MDD, a condition affecting millions around the world, include persistent sadness, lethargy, and feelings of insignificance that adversely affect life quality and increase suicide risk. The current treatment paradigms, including SSRIs and SNRIs, as well as psychotherapy and somatic interventions, provide relief, although they differ in their degrees of effectiveness and onset times. For a significant portion of patients with TRD, however, these conventional methods are ineffective, emphasizing the need for more immediate and efficacious approaches.

Having gained a deeper understanding of MDD, we recognize that monoamine-centric treatments, which focus on the regulation of neurotransmitters such as serotonin and norepinephrine, are often insufficient. This theory does not fully address the neuronal atrophy observed in patients with MDD and TRD, nor does it take into consideration the importance of synaptic regeneration, which is influenced by metabolic glutamate receptors and neurotrophic factors, in areas such as the prefrontal cortex and the hippocampus.

With its rapid action and unique mechanism involving NMDA receptor antagonism, ketamine has been disruptive to this therapeutic landscape, challenging established paradigms. Despite its promise, the complexity of MDD requires a careful and nuanced approach to its application, with an emphasis on further research to ensure that such new treatments can be integrated safely into broader mental health programs.

The clinical efficacy of ketamine and its therapeutic treatment during the course of major depressive disorder (MDD) and suicidality, remains unclear. The issues are (1) whether ketamine-assisted psychotherapy (KAP) enhances or prolongs the antidepressant effects; (2) the therapeutic value of psychedelic protocols that emphasize ketamine’s state-altering properties; (3) the therapeutic potential of ketamine as a first-line treatment for MDD, other mood disorders, and possibly other psychiatric diagnoses; and (4) whether self-administered ketamine can be safely and effectively administered at home.


Hartelius G, Muscat S-A and Bartova L (2023) Editorial: Bridging the gap: an interdisciplinary perspective on ketamine in psychiatric disorders. Front. Psychiatry 14:1246891. doi: 10.3389/fpsyt.2023.1246891 

Lullau, A. P. M., Haga, E. M. W., Ronold, E. H., & Dwyer, G. E. (2023). Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression. Frontiers in neuroscience, 17, 1223145.

Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Jr, Vazquez, G., & Loo, C. (2023). Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine, 62, 102127.

Yavi, M., Lee, H., Henter, I.D. et al. Ketamine treatment for depression: a review. Discov Ment Health 2, 9 (2022).